Program
Click here for the meeting program in PDF.
| Sunday, March 17 | |
| 11:00 – 1:00 | Registration and Poster set-up |
| 1:00 – 1:15 | Welcome – Wayne Tilley (DRMCRL, Adelaide) and Elgene Lim (Garvan Inst, Sydney) |
1:15 – 1:30 |
“Breast and prostate cancer – more similar than different” Theresa Hickey (DRMCRL, Adelaide) and Luke Selth (DRMCRL, Adelaide) |
| 1:30 – 3:00 | Session I: Thousands of genomes – now what? Co-Chairs: Vanessa Hayes (Garvan Inst, Sydney), Ed Gelmann (Columbia Uni, New York) |
| 1. Janet Stanford (Fred Hutch, Seattle) Genetic susceptibility and risk stratification for prostate cancer screening and prevention | |
| 2. Oscar Rueda (CRUK, Cambridge) Statistical approaches to personalised medicine in breast cancer | |
| 3. Felix Feng (UCSF, San Francisco) Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selection | |
| 4. Adrian Lee (UPMC, Pittsburgh) Overcoming inter-patient heterogeneity – intra-patient analysis of breast cancer evolution | |
| General Discussion (40-45 mins) | |
| 3:00 – 3:20 | Coffee Break |
3:20 – 4:50 |
Session II: Estrogen & Androgen receptors: still key drivers? Co-Chairs: Gail Risbridger (Monash Uni, Melbourne), Elgene Lim (Garvan Inst, Sydney) |
| 1. Steffi Oesterreich (Uni of Pittsburgh, Pittsburgh); Estrogen receptor alterations – the most frequent cause of death from breast cancer? | |
| 2. Ganesh Raj (UT Southwestern, Dallas); Overcoming endocrine resistance: masterminds, metaphors and mutants | |
| 3. Theresa Hickey (DRMCRL, Adelaide); When is AR oncogenic in breast cancer? | |
| 4. Steve Balk (Beth Israel DMC, Boston); Persistent AR activity in enzalutamide resistant prostate cancer | |
| 5. Geof Greene (Uni of Chicago, Chicago); Unexpected therapeutic efficacy of a SERM in mutant ER breast cancer | |
| General Discussion (40-45 mins) | |
5:00 – 5:55 |
Flash Talks Co-Chairs: Renea Taylor (Monash Uni, Melbourne), Colleen Nelson (Translational Research Inst / QUT, Brisbane) |
6:00 – 6:45 |
“Ron Ross Award”presentation – Funmi Olopade, MD (University of Chicago) Co-Chairs: Wayne Tilley (DRMCRL, Adelaide), Elgene Lim (Garvan Inst, Sydney) |
| 7:15 – 11:00 | Welcome Reception – Novotel |
| Monday, March 18 | |
| 7:00 – 8:30 | Breakfast |
8:30 – 10:00 |
Session III: Endocrine Resistance – common mechanisms? Co-Chairs: David Waugh (TRI/QUT, Brisbane); Suzanne Fuqua (Baylor College of Medicine, Houston) |
| 1. Rinath Jeselsohn (Dana-Farber Inst, Boston); Endocrine resistance: The most common clinical mechanism | |
| 2. Luca Magnani (Imperial College London, London); Endocrine resistance – common mechanisms? Not really. To each its own, a single cell tale of resistance | |
| 3. Scott Dehm (Uni of Minnesota, Minneapolis); Endocrine uncoupling: When androgen receptors are no longer receptors | |
| 4. Manav Korpal (H3 Biomedicine Inc, Cambridge, USA); Discovery and development of a first-in-class oral selective ERa covalent antagonist (SERCA) for the treatment of ERaWT/MUT b breast cancer | |
| General Discussion (40-45 mins) | |
| 10:00 – 10:30 | Break |
10:30 – 12:00 |
Session IV: Other ‘omics Co-Chairs: Gail Prins (Uni of Illinois, Chicago), Chris Ormandy (Garvan Inst, Sydney) |
| 1. Housheng Hansen He (Uni of Toronto, Toronto); Transcriptomic and functional landscape of circular RNA in prostate and breast cancer | |
| 2. Gavin Ha (Fred Hutch, Seattle); Profiling whole cancer genomes from circulating tumor DNA | |
| 3. Wilbert Zwart (Netherlands Cancer Inst, Amsterdam); Cistromics in clinical trials: Mechanistic insights in tumorigenesis and disease progression | |
| 4. Alex Swarbrick (Garvan Institute, Sydney); Multi-dimensional single cell analysis of the tumour microenvironment | |
| General Discussion (40-45 mins) | |
| 12:00 – 1:10 | Lunch |
1:10 – 2:40 |
Session V: Cell plasticity and tumorigenesis Co-Chairs: Judith Clements (QUT, Brisbane), Greg Goodall (Uni SA, Adelaide) |
| 1. Leigh Ellis (Dana-Farber Inst, Boston); Targeting lineage plasticity in RB1 deficient cancer | |
| 2. Amina Zoubeidi (Uni of BC, Vancouver); Cell plasticity in treatment-resistant prostate cancer | |
| 3. Natasha Kyprianou (Uni of Kentucky, Lexington); Overcoming prostate cancer resistance by phenotypic reprogramming | |
| 4. Jane Visvader (WEHI, Melbourne); Dissecting intraclonal plasticity during breast oncogenesis | |
| General Discussion (40-45 mins) | |
| 2:40 – 3:00 | BioScientifica Presentation |
| 3:00 – 3:30 | Break |
3:20 – 4:50 |
Session VI: Harnessing the immune system Co-Chairs: Mike Brown (Royal Adelaide Hospital, Adelaide), Anthony Joshua (Garvan Inst, Sydney) |
| 1. Shahneen Sandhu (PeterMac, Melbourne); Immunotherapy in prostate cancer: challenges and progress | |
| 2. Anita Dunbier (Uni of Otago, Dunedin); Immune involvement and therapies in ER-positive breast cancer | |
| 3. Belinda Parker (LaTrobe Uni, Melbourne); Reversing tumour invisibility in bone to combat metastatic disease | |
| 4. David Quinn (USC, Los Angeles); Role of tumor blood vessels and response to check point inhibitors | |
| 5. Carlo Palmieri (Uni of Liverpool, Liverpool); Immunotherapy for breast cancer: challenges and opportunities | |
| General Discussion (40-45 mins) | |
7.00 – 11:00 |
Dinner – Chateau Tanunda (Buses depart Novotel from 5.30pm) |
| Tuesday, March 19 | |
| 7:00 – 8:30 | Breakfast |
8:30 – 10:00 |
Session VII: Novel therapeutic targets Co-Chairs: Chris Sweeney (Dana-Farber, Boston), Carlo Palmieri (Uni of Liverpool, Liverpool) |
| 1. Charlotte Bevan (Imperial College, London); MicroRNAs: a potential new therapeutic avenue | |
| 2. Andrei Goga (UCSF, San Francisco); New metabolic and mitotic targets in TNBC | |
| 3. Simak Ali (Imperial College, London); Therapeutic targeting of gene regulatory processes in breast cancer | |
| 4. Geoff Lindeman (WEHI, Melbourne); Targeting cell survival pathways in breast cancer using BH3 mimetics | |
| General Discussion (40-45 mins) | |
| 10:00 – 10:30 | Break |
10:30 – 12:00 |
Session VIII: New instruments in the breast and prostate cancer symphony Co-Chairs: Eva Corey (UWash, Seattle), Stephen Birrell (Uni of Adelaide, Adelaide) |
| 1. David Gallego-Ortega (Garvan Institute, Sydney); A novel biomimetic tissue engineering platform to understand molecular mechanisms of drug resistance at single cell resolution | |
| 2. Richard Iggo (Uni of Bordeaux, Bordeaux); What I cannot create, I do not understand: are MIND models the answer? | |
| 3. Violeta Serra (Vall d’Hebron Institute of Oncology, Barcelona); Challenges and opportunities using ER-positive patient-derived tumour xenoimplant models | |
| 4. Dietmar Hutmacher (QUT, Brisbane); Convergence of regenerative medicine principles to develop new breast and prostate cancer mice models | |
| General Discussion (40-45 mins) | |
| 12:00 – 1:00 | Lunch |
| 1.00 – 4.30 | Free Time |
4.30 – 6:30    |
Poster Session with winetasting by Jo Irvine Lévrier is a James Halliday top 10 new winery in 2019 |
| 7:00 – 11:00 | Dinner – Novotel |
8:15 – 9:30 |
The Great Debate – “Are humans the only model?” Moderator: Chris Sweeney For: Alex Swarbrick, Team Captain Melissa Davis, Scott Dehm, Luca Magnani, Steffi Oesterreich, Amina Zoubeidi Against: Carol Lange, Team Captain Charlotte Bevan, Steve Birrell, Donald McDonnell, Sam Oakes, Wilbert Zwart Judges: Suzanne Fuqua, Geof Greene, Gail Prins, Gail Risbridger (plus one from each Team) |
| Wednesday, March 20 | |
| 7:00 – 8:30 | Breakfast |
8:30 – 10:00 |
Session IX: Nuclear receptors & Co-Regulators: What’s new? Co-Chairs: Carol Lange (Uni of Minnesota, Minneapolis), Robert Matusik (Vanderbilt University, Nashville) |
| 1. Jason Carroll (CRUK, Cambridge, UK); How many associated proteins? What ones are important? | |
| 2. Frank Claessens (KU Leuven Uni, Leuven); Live from an androgen receptor lab: some old news revisited | |
| 3. Carol Sartorius (Uni of Colorado, Denver); PR-RAR crosstalk in breast cancer | |
| 4. Richard Pestell (Baruch S. Blumberg Inst, Philadelphia); DACH1 gene deletion extends portraits of human prostate cancer | |
| 5. Patricia Elizalde (Inst de Biologia y Medicina Experimental, Buenos Aires); My name is ErbB-2, I will be called a transcription factor | |
| General Discussion (40-45 mins) | |
| 10:00 – 10:30 | Break |
10:30 – 12:00 |
Session X: Cellular homeostasis Co-Chairs: Jeff Holst (Uni of NSW, Sydney), Sam Oakes (Garvan Inst, Sydney) |
| 1. Ian Mills (Oxford Uni, Oxford); Contributions of the unfolded protein response and glycosylation to homeostasis | |
| 2. David Thomas (Broad Inst, Boston); Aggressive cancer homeostasis through dynamic flux | |
| 3. Lisa Butler (Uni of Adelaide/SAHMRI, Adelaide); Membrane lipid remodelling: untapped opportunities to predict and disrupt metastasis of hormone-dependent cancers. | |
| 4. Vincent Giguère (McGill Uni, Montreal); The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer? | |
| 5. Donald McDonnell (Duke Uni, Durham); Dyslipidemia and breast cancer pathobiology | |
| General Discussion (40-45 mins) | |
| 12:00 – 1:15 | Lunch |
1:15 – 2:45 |
Session XI: Building a rabbit proof fence: the tumour “terroir” Co-Chairs: Elizabeth Williams (QUT, Brisbane), Robin Anderson (ONJCRI, Melbourne) |
| 1. Leonie Young (RCSI, Dublin); Understanding the transcriptomic circulatory – blocking the rabbit holes early | |
| 2. Pete Nelson (Fred Hutch, Seattle); Intrinsic and extrinsic drivers of micro- and macro-metastasis | |
| 3. Jason Lee (QIMR Berghofer, Brisbane); Harnessing the epigenome: a handbrake for metastasis | |
| 4. Christine Chaffer (Garvan Inst, Sydney); Cancer cell plasticity drives the development of chemoresistance in breast cancer | |
| General Discussion (40-45 mins) | |
| 2:45 – 3:00 | Break |
3.00 – 4.30 |
Inaugural “Rob Sutherland Award” Co-Chairs: David Quinn (USC, Los Angeles), Lisa Horvath (Chris O’Brien LifeHouse, Sydney) |
| 4:45 – 5:00 | TBA: Presenters to be selected from eligible candidates based on submitted abstract and CV |
| 4:30 | Meeting Close |
| 7:00 – 11:00 |
Big Bash Conference Dinner – Seppeltsfield (Buses depart Novotel from 4.45pm) |
| Thursday, March 21 | |
| 7:00 – 9:00 | Breakfast & Check out |
| Approx. 9:30 | Bus to airport / city |